Navigating Aetna Mavyret Prior Authorization for Efficient Approvals
Streamlining the **Aetna Mavyret prior authorization** process is critical for ensuring timely patient access to essential hepatitis C treatment and optimizing revenue cycle performance.
High-volume specialty medications like Mavyret frequently require prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans. For revenue cycle directors and prior authorization coordinators, navigating Aetna's specific requirements, submission channels, and policy nuances is key to minimizing delays and reducing administrative burden.
Understanding Mavyret and Aetna's Coverage Landscape
Mavyret (glecaprevir/pibrentasvir) is a direct-acting antiviral medication used to treat chronic hepatitis C virus (HCV) infection across various genotypes. As a high-cost specialty drug, Mavyret typically requires prior authorization from payers like Aetna to ensure medical necessity and appropriate utilization according to established clinical criteria.
Aetna Prior Authorization Submission Channels for Mavyret
- **Medical Benefit:** For Mavyret administered under the medical benefit, Aetna primarily routes precertification requests through the Availity provider portal. X12 278 transactions via clearinghouses are also supported for certain medical procedures.
- **Pharmacy Benefit:** If Mavyret is covered under the pharmacy benefit, submissions are administered through CVS Caremark, Aetna's PBM. Electronic prior authorization (ePA) can be processed via CoverMyMeds or Surescripts for retail pharmacy claims, or through CVS Caremark's direct provider portal for mail-order scenarios.
- **Specialty Pharmacy Workflow:** Some specialty injectable and infused medications, if applicable, may follow a dedicated specialty-pharmacy-management workflow. The specific benefit assignment (medical vs. pharmacy) should always be verified for Mavyret.
Aetna's Clinical Policy and Utilization Management Criteria
Aetna publishes its medical necessity criteria as Clinical Policy Bulletins (CPBs) within its public CPB library. These CPBs are versioned and dated, serving as the canonical source for medical necessity logic, including any step therapy protocols or quantity limits applicable to drugs like Mavyret. Klivira's platform can help integrate these policy libraries for automated checks.
Navigating Potential Denial Reasons and Appeal Pathways
Common Aetna denial reasons for specialty drugs include insufficient documentation of medical necessity, failure to meet step therapy requirements, or off-label use without compendium support. Denials are communicated via X12 835/277 transactions or portal status updates using CARC and RARC vocabularies. Aetna's appeal pathway typically includes reconsideration, peer-to-peer review, and formal appeal processes, with expedited options for urgent cases.
Turnaround Timeframes and CMS-0057-F Impact
Aetna's prior authorization turnaround times are governed by state insurance regulations for commercial plans and NCQA Utilization Management accreditation standards. For Medicare Advantage and Medicaid managed-care lines, Aetna is an impacted payer under CMS-0057-F, which mandates 72-hour decisions for standard PA requests and 24-hour for expedited requests, with phased compliance through 2027 for electronic PA API conformance.
Frequently asked questions
How does Klivira help with Aetna Mavyret prior authorization?
Klivira automates the submission of Aetna Mavyret prior authorizations by integrating with key channels like the Availity portal and ePA partners such as CoverMyMeds and Surescripts. Our platform streamlines documentation gathering and submission, reducing manual effort and accelerating approval times.
Where can I find Aetna's specific criteria for Mavyret?
Aetna's medical necessity criteria for Mavyret, including any step therapy requirements or quantity limits, are published in their Clinical Policy Bulletins (CPBs) available in the public Aetna CPB library. It is essential to reference the specific CPB number and review date for the most current guidelines.
What are the common reasons for Aetna Mavyret prior authorization denials?
Common denial reasons for Aetna Mavyret prior authorizations often include insufficient documentation to support medical necessity, failure to adhere to step therapy protocols, or situations where the requested use is off-label without adequate compendium support. Klivira helps identify and address these issues proactively.
Does Aetna support electronic prior authorization (ePA) for Mavyret?
Yes, Aetna supports ePA for Mavyret under the pharmacy benefit through partners like CoverMyMeds and Surescripts. For medical benefit prior authorizations, Klivira integrates with the Availity provider portal and supports X12 278 transactions to facilitate electronic submissions.
What is the typical turnaround time for an Aetna Mavyret prior authorization?
Turnaround times vary based on the line of business and urgency. For commercial plans, state regulations and NCQA standards apply. For Medicare Advantage and Medicaid, Aetna must adhere to CMS-0057-F mandates of 72 hours for standard and 24 hours for expedited requests, with full electronic PA API conformance by 2027.
Related coverage
Other mavyret prior authorization by payer
- Anthem (Elevance Health) Mavyret Prior Authorization: A Strategic Approach
- Navigating Cigna Mavyret Prior Authorization for Hepatitis C Treatment
- Streamlining Humana Mavyret Prior Authorization Workflows
- Streamlining Medicaid Mavyret Prior Authorization Workflows
- Streamlining Medicare Mavyret Prior Authorization Workflows
- Streamlining UnitedHealthcare Mavyret Prior Authorization
Other mavyret prior authorization by specialty
- Optimizing Mavyret Prior Authorization for Cardiology Patient Populations
- Mavyret Prior Authorization for Endocrinology: Optimizing Workflow
- Streamlining Mavyret Prior Authorization for Gastroenterology
- Streamlining Mavyret Prior Authorization for Oncology Patients
- Mavyret Prior Authorization for Orthopedics: Streamlining Co-managed Patient Care
Ready to automate prior auth for this drug?
See how Klivira automates prior authorizations for your team.
Request a demo